| NovoSeven (eptacog alfa) / Novo Nordisk |
2019-003427-38: An international investigator trial to capture different approaches in the treatment of Hemophilia A Patients With FVIII Inhibitors |
|
|
| Ongoing | 4 | 120 | Europe, RoW | Octanate, Wilate, Nuwiq, Hemlibra, NovoSeven, Powder and solvent for solution for injection, Solution for injection, Octanate, Wilate, Nuwiq, Hemlibra, FEIBA NF 500 E/1000 E, NovoSeven | HZRM – Hämophilie-Zentrum Rhein Main GmbH, Octapharma AG | Inhibitor-Positive patients with Haemophilia A, Haemophilia A in patients who have developed inhibitors to any FVIII product., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2019-003722-25: Recombinant Factor VIIa for acute bleeding in the brain (Hemorrhagic Stroke) administered at earliest Time - (FASTEST) Trial |
|
|
| Not yet recruiting | 3 | 860 | Europe, RoW | NovoSeven 5mg (250 KIU), Powder and solvent for solution for injection, NovoSeven 5mg (250 KIU) | University of Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS), NovoNordisk A/S, National Institute of Neurological Disorders and Stroke, NINDS, Novo Nordisk A/S | Acute Hemorrhagic Stroke, Acute bleeding into the brain, Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-002854-22: CLINICAL TRIAL COMPARING PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY OFA BIOSIMILAR EPTACOG ALFA (ARYOSEVEN) AND NOVOSEVEN®, INPATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS |
|
|
| Not yet recruiting | 3 | 48 | Europe | AryoSeven, NovoSeven, Powder and solvent for solution for injection, NovoSeven | Aryogen Pharmed, Aryogen Pharmed | HAEMOPHILIA A OR B WITH INHIBITORS, HAEMOPHILIA A OR B WITH INHIBITORS, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
| Recruiting | 3 | 860 | Europe, Canada, Japan, US | Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo | Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS) | Intracerebral Hemorrhage | 01/28 | 01/28 | | |
2013-005036-20: Recombinant Factor VIIa: Local treament of severe bleedings after delivery |
|
|
| Ongoing | 2 | 10 | Europe | Recombinant Activated Factor VII, NovoSevenRT, NovoSevenRT | Stellaris Pharmaceuticals ApS, Stellaris Pharmaceuticals ApS | Severe postpartum bleeding Desuden indgår 5 personer, der får foretaget sektio af anden årsag, som kontrol med hensyn til måling af koagulationsparametre inden og 15 minutter efter fjernelse af placrenta. | | | | |
NCT06010953: SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment |
|
|
| Completed | 1/2 | 24 | RoW | SS109 | Jiangsu Gensciences lnc. | Male, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Hemophilia | 05/24 | 05/24 | | |
NCT04768699: Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. |
|
|
| Recruiting | 1 | 24 | RoW | TQG203, TQG203/NovoSeven® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | 12/21 | 12/21 | | |
| Recruiting | N/A | 120 | Europe, US | Nuwiq, Octanate, Wilate, Emicizumab, Hemlibra, Recombinant factor VIIa (rFVIIa), NovoSeven, Activated prothrombin complex concentrate (aPCC), FEIBA | Emory University, Octapharma | Hemophilia A | 12/28 | 06/29 | | |
